Project 2: Near-Infrared Targeted Tracers for Intraoperative Identification of NSCLC
项目2:用于术中识别NSCLC的近红外靶向示踪剂
基本信息
- 批准号:10647645
- 负责人:
- 金额:$ 41.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-16 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAdenocarcinomaAnimal HospitalsAnimal ModelAntigensApplications GrantsBiopsyBronchoscopyCancer EtiologyCancer ModelCancer PatientCancerousCanis familiarisCessation of lifeClinicClinicalClinical TrialsColon CarcinomaContrast MediaDataDetectionDevelopmentDiseaseDoseDrug KineticsDyesEnsureFOLH1 geneFOLR1 geneFibroblastsFluorescenceFluorochromeFolic AcidFormulationGenetic HeterogeneityGoalsGrantHumanImageImage-Guided SurgeryIn VitroInstitutionInterventionLibrariesLogisticsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMalignant neoplasm of prostateMembraneMolecularMolecular ProbesMusNoduleNoiseNon-Small-Cell Lung CarcinomaOperative Surgical ProceduresOpticsPathologicPatient AgentsPatientsPersonsPhenotypePopulationProceduresReproducibilityResearchSecond Primary CancersSensitivity and SpecificityTestingTimeTissuesTracerTranslationsUnited StatesVisualVisualizationWorkXenograft procedurebiomaterial compatibilitycancer cellcancer imagingcancer surgerycancer typecarbonate dehydratasechemical synthesisclinical applicationefficacy testingenvironmental tobacco smoke exposureexperienceexperimental studyfibroblast-activating factorfolate-binding proteinhuman modelimage guidedimprovedinnovationlung cancer celllung imaginglymph nodesmalignant breast neoplasmmolecular imagingmouse modelnear infrared dyephase 2 studypre-Investigational New Drug meetingpre-clinicalprogramsreceptorsuccesstargeted agenttumor
项目摘要
Project Summary
Our goal is to develop a fluorescence guided imaging solution to lung cancer. Each year, lung cancer
is the biggest cause of cancer related deaths in the US (>160,000 people) and the world (1.4 million
fatalities). The primary strategy in this Project is to develop, characterize and test a combination of four
targeted near-infrared contrast agents that will be used in humans to improve procedures for patients
with lung cancer. It is clear that using fluorescent targeted agents during cancer surgery can highlight
cancer cells for clinicians, thus several groups are testing molecular probes. Our research will
specifically focus on lung cancer. Lung cancer is a very heterogeneous tumor due to the wide range
of offending agents that can cause this disease. The proposed work will optimize four distinct types of
contrast agents in a combination or cocktail for a translational intraoperative imaging clinical trials. The
first cocktail agents are composed of folate and GCPII conjugated to a NIR dye. These two contrast
agents are fully functional and are in human trial. However, together, they still miss a significant
proportion of patients with lung cancer. Thus, we will be focusing our efforts on two more agents, CAIX
and FAP, in this proposal. The goal of this Aim is to integrate the NIR tracers that are ready for clinical
use. We will be utilizing both murine models and spontaneous lung cancer models in pet canines.
Integration of these four agents will require studying the changes in sensitivity and specificity. It will
also require examining the timing of these agents and the interactions of these tracers. If this cocktail
is successful, it will provide a complete solution for the number one cancer killer in the United States.
项目概要
我们的目标是开发一种针对肺癌的荧光引导成像解决方案。每年都有肺癌
是美国(>160,000 人)和世界(140 万人)癌症相关死亡的最大原因
死亡人数)。该项目的主要策略是开发、表征和测试四种组合
靶向近红外造影剂将用于人体以改善患者的手术
患有肺癌。很明显,在癌症手术期间使用荧光靶向剂可以突出显示
为临床医生提供癌细胞,因此几个小组正在测试分子探针。我们的研究将
特别关注肺癌。肺癌是一种异质性很强的肿瘤,其发病范围广泛。
可能导致这种疾病的致病因素。拟议的工作将优化四种不同类型的
用于转化性术中成像临床试验的组合或混合物中的造影剂。这
第一种鸡尾酒制剂由叶酸和与近红外染料缀合的 GCPII 组成。这两个对比
药剂功能齐全,正在进行人体试验。然而,他们仍然错过了一个重要的
肺癌患者的比例。因此,我们将把精力集中在另外两个代理上:CAIX
和 FAP,在本提案中。该目标的目标是整合可供临床使用的 NIR 示踪剂
使用。我们将在宠物犬中使用小鼠模型和自发性肺癌模型。
这四种药物的整合需要研究敏感性和特异性的变化。它将
还需要检查这些代理的时间安排以及这些示踪剂的相互作用。如果这杯鸡尾酒
如果成功,将为美国头号癌症杀手提供完整的解决方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILIP Stewart LOW其他文献
PHILIP Stewart LOW的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILIP Stewart LOW', 18)}}的其他基金
Project 2: Near-Infrared Targeted Tracers for Intraoperative Identification of NSCLC
项目2:用于术中识别NSCLC的近红外靶向示踪剂
- 批准号:
10333065 - 财政年份:2022
- 资助金额:
$ 41.25万 - 项目类别:
Near infrared intraoperative molecular imaging of lung adenocarcinoma
肺腺癌近红外术中分子影像
- 批准号:
9198209 - 财政年份:2016
- 资助金额:
$ 41.25万 - 项目类别:
Near infrared intraoperative molecular imaging of lung adenocarcinoma
肺腺癌近红外术中分子影像
- 批准号:
9030040 - 财政年份:2016
- 资助金额:
$ 41.25万 - 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
- 批准号:
6712779 - 财政年份:2002
- 资助金额:
$ 41.25万 - 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
- 批准号:
6622784 - 财政年份:2002
- 资助金额:
$ 41.25万 - 项目类别:
Tumor-Specific Targeting of Folate-Derivatized Drugs
叶酸衍生药物的肿瘤特异性靶向
- 批准号:
6455374 - 财政年份:2002
- 资助金额:
$ 41.25万 - 项目类别:
RED CELL TYROSINE KINASES AND REGULATION OF METABOLISM
红细胞酪氨酸激酶和代谢调节
- 批准号:
2180639 - 财政年份:1988
- 资助金额:
$ 41.25万 - 项目类别:
RED CELL TYROSINE KINASES AND REGULATION OF METABOLISM
红细胞酪氨酸激酶和代谢调节
- 批准号:
3298949 - 财政年份:1988
- 资助金额:
$ 41.25万 - 项目类别:
RED CELL TYROSINE KINASES AND REGULATION OF METABOLISM
红细胞酪氨酸激酶和代谢调节
- 批准号:
3298950 - 财政年份:1988
- 资助金额:
$ 41.25万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Interactions Between the Microbiota and Helicobacter pylori in Gastric Carcinogenesis
微生物群与幽门螺杆菌在胃癌发生中的相互作用
- 批准号:
10709135 - 财政年份:2023
- 资助金额:
$ 41.25万 - 项目类别:
Multiscale modeling of spatiotemporal evolution in Barrett's esophagus
巴雷特食管时空演化的多尺度建模
- 批准号:
10659649 - 财政年份:2023
- 资助金额:
$ 41.25万 - 项目类别:
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
配体导向的 KRAS G12V 突变特异性治疗
- 批准号:
10757070 - 财政年份:2023
- 资助金额:
$ 41.25万 - 项目类别:
Enhancing the Effectiveness of Immunotherapies by T Cell Epigenetic Reprogramming
通过 T 细胞表观遗传重编程增强免疫疗法的有效性
- 批准号:
10737264 - 财政年份:2023
- 资助金额:
$ 41.25万 - 项目类别:
The role of translation initiation factor eIF5B in lung cancer pathogenesis
翻译起始因子eIF5B在肺癌发病机制中的作用
- 批准号:
10734752 - 财政年份:2023
- 资助金额:
$ 41.25万 - 项目类别: